BioSpace News Archive

Agomab Therapeutics NV announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal -restricted small molecule kinase inhibitor of ALK5, intended for the treatment of Fibrostenosing Crohn’s Disease.

Know Labs, Inc., an emerging developer of non-invasive medical diagnostic technology, shared an update on its strategic partnerships with leading experts in data science, sensor technology, product design and regulatory affairs.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”) announced today that it will be hosting a booth at the upcoming Medlab Middle East 2023 trade show held February 6-9 at the Dubai World Trade Centre.

Menopause: The Journal of the North American Menopause Society today published “Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1),” detailing the results of the SWITCH-1 clinical trial aimed at identifying effective dosing for the investigational compound elinzanetant, a non-hormonal, selective neurokinin 1,3 receptor antagonist.

ams OSRAM, a global leader in optical solutions, introduced the AS5911, a 256-channel analog-to-digital converter for digitizing signals from photodiode arrays in high-performance computed tomography scanners.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PLN-101095, an oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.

Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will provide a corporate update at the BIO CEO & Investor Conference being held both virtually and in New York, NY on February 6-9, 2023.

Achieve Life Sciences, Inc. today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has entered into an agreement with Lexitas Pharma Services, Inc. (“Lexitas”)

Medline announced a new partnership with MDHearing, a direct-to-consumer hearing aid manufacturer, to make it easier for people to purchase affordable hearing aids without a prescription.